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Abstract
With 19–25 nucleotides long, microRNAs (miRNAs) are small noncoding RNA molecules 
which play crucial roles in major cellular functions such as cell cycle control, apoptosis, 
metabolism, cell proliferation, and cell differentiation. Changes in the expression of 
miRNAs can cause significant effects to normal and aberrant cells. The dysregulation 
of miRNAs has been implicated in various human diseases such as brain tumor, osteo-
arthritis, schizophrenia, and breast cancer. Generally, miRNAs negatively regulate gene 
expression by binding to their specific mRNAs, thereby blocking their translation of the 
mRNAs. However, a few studies have reported that miRNAs could also upregulate the 
translation of certain proteins. This shows the important roles of miRNAs in various cell 
functions. This chapter will focus on the role of miRNAs in normal osteoblast and osteo-
sarcoma cells. In addition, the great potential of miRNA as a new therapeutic approach 
to treat human bone diseases will also be discussed.
Keywords: microRNAs, bone diseases, osteoblasts, osteoclasts, bone homeostasis, gene 
regulation
1. Introduction
MicroRNAs (miRNAs) are short (19–25 nucleotides) single-stranded noncoding RNA mol-
ecules that regulate protein expression by complementary binding to mRNA targets with 
the aid of RNA-induced silencing complex (RISC) [1]. When miRNAs pair perfectly with 
mRNA targets, mRNAs degradation will occur. Translational repression of gene will happen 
when miRNAs bind partially complementary to mRNA targets [2]. Since the discovery of the 
first miRNA, lin-4 in Caenorhabditis elegans in 1993, thousands of miRNAs have been identi-
fied in animals and plants [3]. These miRNAs play crucial roles in biological processes such 
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as cell growth, cell formation and differentiation, apoptosis, and cell metabolism. MiRNAs 
also regulate bone cells such as osteoblasts, osteoclasts, and osteocytes, which function in 
the mechanism of bone modeling and bone remodeling [4]. Osteoblasts play important roles 
in bone formation and osteoclasts function in bone resorption, whereas osteocytes regu-
late osteoblasts and osteoclasts activities by controlling signaling pathways [4] (Figure 1). 
Expression of many miRNAs has been found to be upregulated or downregulated in bone 
cancer cells compared to normal bone cells. Some of these miRNAs act as oncogenes such 
as miR-27, which promote the migration and invasion ability in the osteosarcoma [5]. Some 
other miRNAs act as tumor repressor genes such as miR-192 and miR-215, which play major 
roles in cell cycle arrest in cancer cells [6]. Dysregulation of miRNA expression by specific 
translation regulation such as DNA methylation, which leads to miRNA silencing, has been 
associated with bone diseases such as osteoporosis, osteogenesis imperfecta, and osteoarthri-
tis [4, 7]. Therefore, understanding the roles of miRNAs in bone cells will provide the oppor-
tunity to develop miRNA-based therapy for bone diseases. In this chapter, we highlight the 
roles of various miRNAs that involve in the formation, resorption, and maintenance of bone 
in various bone diseases.
2. Regulatory role of microRNAs in normal bone growth and 
maintenance
Bone is a dynamic tissue that undergoes constant processes of modeling and remodeling 
throughout life. Bone modeling is the process where bones resculpture or rechange its overall 
size and shape as an adaptive mechanism against physiological processes or biomechanical 
influences, customizing or adjusting the skeleton toward the actions in which it encounters 
[8]. Bones may widen, change axis, or alter curvature by an independent action of osteoblasts 
and osteoclasts in response to biomechanical forces [9]. Bone modeling aids in the preven-
tion of damage or injury to the bone [10] and regulates growth phase such as facilitating the 
increase in a child’s skull size to accommodate the bigger brain as a child grows and under-
goes marked change in the facial features of a child to that as an adult [11].
Meanwhile, bone remodeling is a sequential process, which involves the removal of the old 
bone (bone resorption) and the deposition of new bone (bone formation) [10, 12]. This process 
is ultimately important for the maintenance of the bone’s strength and integrity by modulat-
ing the reshaping or replacement of bone during growth, preventing the accumulation of 
bone microdamage and regulating mineral homeostasis [8]. Bone remodeling is a lifelong, 
bone turnover [13] that is tightly regulated by two main population of bone cells: the bone-
resorbing osteoclasts of hematopoietic lineage and the bone-forming osteoblasts of mesenchy-
mal lineage [14, 15]. This tightly coupled process requires synchronized activities, balanced 
by both of these effector cells [8].
MicroRNAs serve as positive and/or negative regulators for various musculoskeletal signal-
ing pathways or mechanisms by regulating bone biology such as in osteoblastic or osteoclas-
tic differentiation, in accordance with the orchestrated balance between bone resorption and 
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bone formation. MiRNAs are known to be involved in the osteoclast-mediated bone resorp-
tion by regulating macrophage colony-stimulating factor (M-CSF) and receptor activator of 
NF-κB ligand (RANKL)-induced signaling pathways, which involved in the commitment of 
osteoclasts from osteoclast progenitors [16].
2.1. MicroRNA roles in normal bone resorption
The receptor activator of NF-κB ligand (RANKL) and macrophage colony-stimulating fac-
tor (M-CSF) signaling pathway are the principle operating pathways that regulate osteoclast 
differentiation and activation in bone remodeling [16]. These signaling pathways are tightly 
regulated by microRNAs. Hence, the involvement of miRNAs in the process of osteoclasts 
differentiation is crucial for normal bone resorption.
MiR-31 has been identified to be significantly upregulated in mice bone marrow cells under 
RANKL-induced osteoclast formation. The suppression of miR-31 by specific antagomirs 
under receptor activator of NF-κB ligand (RANKL) treatment decreased the number of tar-
trate-resistant acid phosphatase (TRAP)-positive multinucleated osteoblastic cells and ring-
shaped mature osteoclastic cells. Additionally, less efficient resorption of synthetic calcium 
phosphate matrix and impaired actin ring formation for the development bone resorption 
sealing zone were also reported following the miR-31 antagomir transfection. In this situation 
of impaired osteoclastogenesis, the Ras homolog gene family member A (RhoA), which is the 
target of miR-31, was upregulated. Interestingly, treatment with RhoA inhibitor, coenzyme C
3
 
was able to rescue the decrease in number of ring-shaped TRAP-positive multinucleated cells 
and potentially revert the osteoclastogenesis impairment [17].
During the late stage of osteoclastogenesis, the osteoclasts undergo apoptosis to allow the 
reversal phase of bone remodeling, which allows the transition of bone resorption to bone for-
mation [8]. At this stage, there is a significant upregulation of miR-26a under RANKL stimula-
tion. Treatment with an miR-26a mimic in preosteoclast cells (pre-OCs) significantly inhibited 
the formation of osteoclast, peripheral actin ring, and resorption pit, whereas treatment with 
miR-26a inhibitor dramatically reversed these observations. The study proposed that miR-26a 
suppressed osteoclasts formation in the late stage of bone remodeling by targeting connective 
tissue growth factor/CCN family 2 (CTGF/CCN2), which plays an important role in promot-
ing osteoclast formation via upregulation of dendritic cell-specific transmembrane protein 
(DC-STAMP) [18].
Another miRNA, miR-21 has been shown to be upregulated by RANKL-induced osteoclas-
togenesis in mouse osteoclast precursor cells’ bone marrow-derived macrophages (BMMs). 
MiR-21 downregulates the expression of programmed cell death 4 (PDCD4), which is a 
repressor for c-Fos. The activated c-Fos, an important transcription factor for osteoclasto-
genesis, allows RANKL to induce nuclear factor of activated T-cells cytoplasmic 1 (NFATc1) 
mRNA expression and stimulates osteoclast-specific markers such as tartrate-resistant acid 
phosphatase (TRAP) and cathepsin K. The silencing of miR-21 by transduction of BMMs with 
antisense oligonucleotides of miR-21 inserted in a lentiviral vector increased the expression of 
PDCD4 and impaired the RANKL-induced osteoclastogenesis [19].
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In another study, the overexpression of miR-148a was observed during M-CSF and RANKL-
stimulated osteoclast differentiation in CD14+ peripheral blood mononuclear cell (PBMCs). 
The overexpression of miR-148a induced the formation of osteoclast, whereas suppression of 
miR-148a showed an opposite outcome. In vivo study using ovariectomized (OVX) mice that 
undergoes intravenous injection with specific miR-148a silencing antagomir showed reduction 
in bone resorption and increase in bone mass density (BMD). Furthermore, osteoclasts number 
and the levels of osteoclast activity markers such as tryptophan-regulated attenuation protein 
(TRAP) and nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1) mRNA in bone tissue 
were also decreased following antagomiR-148a treatment. This finding shows that decreased 
miR-148a levels impaired bone resorption through suppression of osteoclast activity. MiR-148a 
performs its regulatory role by targeting 3′UTR of V-maf musculoaponeurotic fibrosarcoma 
oncogene homolog B (MAFB), a negative regulator of osteoclastogenesis and resulted in an 
inhibited expression of MAFB protein [20]. Additionally, MAFB serves as a negative regulator 
in RANKL-induced osteoclastogenesis by interfering the DNA binding capability of the three 
major transcription factors; NFATc1, c-Fos, and MITF in osteoclast differentiation [21].
The relative expression of miR-340 was downregulated upon M-CSF and RANKL-induced 
osteoblast differentiation in BMMs. It has been reported that the overexpression of miR-340 
inhibits osteoclast differentiation and reduced the number of osteoclasts cells by target-
ing 3′UTR of microphthalmia-associated transcription factor (MITF), a transcription factor 
involved in osteoclast differentiation, leading to the reduced level of MITF mRNA and pro-
tein. MITF knockdown will inhibit TRAP, calcitonin receptor, V-ATPase d2, and cathepsin 
K expression, and thus, suggested that miR-340 may suppress osteoclast differentiation by 
targeting MITF [22].
2.2. MicroRNAs in normal bone formation
Canonical wnt/β-catenin signaling pathway is a major pathway required for the commit-
ment of mesenchymal stem cells into osteoblast lineage [15]. The stabilization of β-catenin 
is important for the expression of wnt-responsive gene [16]. The miR-29 family is one of the 
well-known miRNA families that regulate osteoblast function, which plays a key role in the 
positive regulation of osteoblast differentiation by targeting several wnt-signaling pathway 
inhibitors. The expression of miR-29a is induced by canonical wnt signaling during osteoblast 
differentiation and has been shown to target dikkopf-1 (Dkk1), Kringle domain-containing 
transmembrane protein (Kremen2), and secreted frizzled related protein 2 (sFRP2), which 
acts as inhibitors of wnt receptor complex [23]. Moreover, miR-29b was also found to target 
several other inhibitors of bone formation such as histone deacetylase 4 (HDAC4), transform-
ing growth factor beta 3 (TGFβ3), activin receptor type-2A (AcvR2A), beta-catenin-interacting 
protein 1 (CTNNBIP1), and dual specific phosphatase 2 (DUSP2) by binding to their mRNA 
3’UTR [24]. Furthermore, the expression level of miR-29 is low during the early phase of osteo-
blastogenesis and increases at late phase, as miR-29 targets α1 and α2(I)collagen, α1(III)colla-
gen, fibrillin 1, and osteonectin, which are important for the formation of collagen fibril matrix 
secreted by osteoblasts, and thus allowed for collagen matrix deposition before subsequent 
mineralization in bone formation process [25]. Therefore, miR-29 family is important in the 
promotion of osteoblastogenesis by repressing the inhibitors of osteogenesis and in the mean-
while plays crucial regulatory role in the attenuation of collagen synthesis in mineralized bone.
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On the other hand, bone morphogenetic protein (BMP)-signaling pathway is crucial for 
the differentiation of myoblastic cell lines into osteoblast lineage and bone formation [16]. 
MiR-133 and miR-135 are downregulated in BMP-2-induced osteoblastic differentiation of 
C2C12 pluripotent mesenchymal cell line. MiR-133 is a negative regulator of Runt-related 
transcription factor 2 (Runx2), a transcription factor required for osteoblast differentiation, 
while miR-135 represses the osteoblastic differentiation of C2C12 cells by acting toward 
mothers against decapentaplegic homolog 5 (Smad5), an intracellular Runx2 co-receptor. 
Hence, downregulation of miR-133 and miR-135 will increase the expression of Runx2 and 
Smad5, promoting the BMP-2-induced osteoblast differentiation. Moreover, the overexpres-
sion of these miRNAs will suppress the expression of BMP-induced osteoblast-specific pro-
tein markers such as alkaline phosphatase (ALP), osteocalcin, and homeobox A10 (HOXA10) 
[26]. Another miRNA, miR-20 has been shown to involve in the transformation of osteoblast 
from human MSCs by downregulating the expression of silencing peroxisome proliferator-
activated receptor γ (PPARγ), bone morphogenetic protein and activin membrane-bound 
inhibitor (Bambi), and cysteine-rich transmembrane BMP regulator 1 (Crim1) and therefore, 
activated the BMP-2/Runx2 signaling [27].
Another report showed that miR-2861 expression was elevated in primary mice osteoblasts. 
Overexpression of miR-2861 in mice bone marrow stromal cells (BMSCs) has been reported 
to promote BMP2-induced osteoblast differentiation. Conversely, the inhibition of miR-2861 
expression results in the decrease in osteoblast differentiation. In vivo knockdown of miR-
2861 in OVX mice resulted in enhanced decrement of bone volume and bone formation rate. 
Furthermore, histone deacetylase 5 (HDAC5) has been identified as the direct target of miR-
2861. HDAC5 deacetylates Runx2 and allow the deacetylated Runx2 to undergo SMAD specific 
E3 ubiquitin protein ligase 1 (Smurf1)-mediated degradation, decreasing the rate of osteoblast 
differentiation. Therefore, the abundance of acetylated Runx2 will increase upon HDAC5 
suppression by miR-2861 and promote osteoblast differentiation [28]. MiR-3960 is generated 
Figure 1. The process of bone remodeling begins with the recruitment of osteoclast progenitor cells to the site of bone 
remodeling, followed by osteoclast progenitor cells differentiation into mature osteoclasts. Reversal phase allows the 
transition from bone resorption phase to bone formation phase. In bone formation phase, mesenchymal stem cells 
differentiate into mature osteoblast and secrete collagenous components for bone formation. Bone remodeling process is 
completed after the mineralization of collagen fibril matrix and subsequent transformation of osteoblasts into osteocytes.
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from the same genetic locus as the miR-2861 due to the transcription from the same primary 
microRNA (pri-miRNA). MiR-3960 was found to directly target homeobox A2 (HOXA2), a 
negative regulator of Runx2. Hence, the miR-3960-mediated suppression of HOXA2 by miR-
3960 will increase Runx2 expression and osteoblast differentiation [29]. The summary of the 
MicroRNAs involved in the regulation of normal bone development is shown in Table 1.
MicroRNAs Target gene or protein 
encoded
Associated event Reference
MicroRNAs associated with bone resorption
MiR-31 RhoA Promotes osteoclast differentiation by targeting 
RhoA
[17]
MiR-26a CTGF/CCN2 Inhibits osteoclast differentiation by targeting CTGF/
CCN2
[18]
MiR-21 PDCD4 Promotes osteoclast differentiation by targeting 
PDCD4
[19]
MiR-148a MAFB Promotes osteoclast differentiation by targeting 
MAFB
[20]
MiR-340 MITF Inhibits osteoclast differentiation by targeting MITF [22]
MicroRNAs associated with bone formation
MiR-29 COL1A1, COL3A1, 
fibrillin 1, osteonectin
Downregulated during the early phase of bone 
formation and upregulated during the late phase 
by targets COL1A1, COL3A1, fibrillin 1, and 
osteonectin to allow the formation of collagen fibril 
matrix
[25]
MiR-29a Dkk1, Kremen2, sFRP2 Promotes osteoblasts differentiation by targeting 
Dkk1, Kremen2, sFRP2 inhibitors of wnt signaling 
pathway
[23]
MiR-29b HDAC4, TGFβ3, 
AcvR2A, CTNNBIP1, 
DUSP2
Promotes osteoblasts differentiation by inhibitors of 
bone formation such as HDAC4, TGFβ3, AcvR2A, 
CTNNBIP1, and DUSP2
[24]
MiR-133 Runx2 Inhibits osteoblast differentiation by targeting Runx2 [26]
MiR-135 Smad5 Inhibits osteoblast differentiation by targeting 
Smad5
[26]
MiR-20 PPARγ, Bambi, Crim1 Promotes osteoblast differentiation by targeting 
PPARγ, Bambi and Crim1
[27]
MiR-2861 HDAC5 Promotes osteoblasts differentiation by targeting 
HDAC5, which represses Runx2
[28]
MiR-3960 Hoxa5 Promotes osteoblasts differentiation by targeting 
Hoxa5, which represses Runx2
[29]
Table 1. MicroRNAs involved in the regulation of normal bone development.
Transcriptional and Post-transcriptional Regulation82
3. MicroRNAs’ expression in various bone diseases
Dysregulation of miRNAs affects critical pathways and biological processes, which lead to 
various bone diseases. MiRNA profiling studies have revealed that miRNA expression pat-
terns are specific to various types of bone diseases, and it reflects the developmental lineage 
and pathway that lead to the diseases.
3.1. Benign bone tumor: giant cell tumor
Giant cell tumor of bone (GCTB) is an aggressive benign tumor that is able to metastasize, and 
up to 6% of GCTB patients grow pulmonary metastases (metastatic spread via blood or lym-
phatics) [30]. GCTBs are characterized by the presence of numerous multinucleated osteoclast-
like giant cells distributed among mononuclear stromal cells [31]. GCTBs are also characterized 
by extensive bone resorption, which results in regional pain and bone destruction, mostly 
occurring in distal femur, proximal tibia, distal radius, and sacrum [32, 33]. Histologically, 
GCTBs can be classified into three main types, which are osteoclast-like multinucleated giant 
cells, monocytic round cells, and spindle-like stromal cells [34]. Current treatments of GCTBs 
are ranging from intralesional curettage to wide resection [33]. Since the cause of GCTBs is 
extensive bone resorption by aggressive lytic process, the repression of osteoclastogenesis 
becomes a potential approach to cure GCTBs [30].
A study reveals that treatments with miR-16-5p mimic repressed RANKL-induced osteoclasto-
genesis in GCTBs. However, the formation of RANKL-induced osteoclast was enhanced with 
miR-16-5p inhibitor. Furthermore, the osteoclastogenesis-related genes like cathepsin K (CK), 
tartrate-resistant acidic phosphatase (TRAP), and matrix metallopeptidase 9 (MMP9) were also 
upregulated by miR-16-5p inhibitor. This finding shows that miR-16-5p inhibits osteoclasto-
genesis; hence, it has the potential to be used as a therapeutic target to control the excessive 
bone resorption in GCTBs [30]. Another study by Wang et al. found that miR-106b is another 
microRNA that target RANKL to inhibit osteoclastogenesis and osteolysis in GCTBs [32].
Parathyroid hormone 1 receptor (PTH1R) is a transmembrane receptor that binds to G pro-
teins. The activation of pathways that promote osteoclastogenesis in osteoblasts is induced 
when PTH binds to parathyroid hormone 1 receptor (PTH1R). Wu et al. reported that miR-
125b directly targets the 3′UTR of PTH1R. Overexpression of tumor suppressor miR-125b 
inhibits the osteoclastogenesis and also PTH1R downstream target such as RANKL and IL-8 
[35]. The downregulation of miR-125b in GCTBs revealed that it suppressed the cell growth 
and proliferation in GCTBs.
3.2. Bone remodeling abnormality: osteoporosis
Osteoporosis is a multifactorial bone disorder characterized by low bone mass, impaired 
bone quality, and a more susceptibility to fracture [36]. The recent global statistics from the 
International Osteoporosis Foundation reported that 1 in 3 women and 1 in 5 men above the 
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age of 50 will suffer from osteoporotic fractures in their lifetime [37]. The primary osteopo-
rosis is generally arising due to the postmenopausal deficiency or loss of sex hormones such 
as estrogen, while the secondary osteoporosis is due to the presence of underlying diseases 
and medication of treatments with glucocorticoids, hyperthyroidism, diabetes mellitus, and 
gastrointestinal disorders [37, 38]. The bone mineral density peaks during adolescence stage 
of puberty, which then maintained throughout an individual middle age for some decades 
and subsequently begins to loss upon aging. Bone tissue undergoes continuous process of 
resorption and formation throughout in an individual lifetime. Osteoporosis occurs when 
bone resorption rate exceeds the bone formation rate, resulting in a net loss of bone [39]. 
Studies revealed that osteoporosis incidences may be linked to bone mass-related genetic 
determinants including low-density lipoprotein receptor-related protein 5 (LRP5), osteopro-
tegerin (OPG), sclerostin (SOST), estrogen receptor 1, and the receptor activator of RANK/
NF-κB signaling pathway [40].
Receptor activator of nuclear factor kappa-Β ligand (RANKL) binds to the receptor activator 
of nuclear factor κB (RANK) that is present on the surface of the osteoclast mononuclear 
precursor cells and facilitates the formation of fully differentiated osteoclasts [41]. The expres-
sion of mirR-503 is significantly reduced in progenitors of osteoclasts-CD14+ peripheral blood 
mononuclear cells (PBMCs) of postmenopausal osteoporosis patients compared to healthy 
postmenopausal controls. The overexpression of miR-503 in human PBMCs had dramatically 
inhibited RANKL-induced osteoclast differentiation in PBMCs of postmenopausal osteopo-
rosis samples. In vivo transfection of miR-503 silencing antagomir into a postmenopausal-
stimulated ovariectomized (OVX) mice resulted in the increase in RANK protein expression, 
an increase of bone resorption rate, a decrease in bone mass, and an aggravation of bone loss. 
Contrastingly, the transfection of the OVX mice with miR-503 overexpressing pre-miR-503 
leads to the decrease in RANK protein expression and thus a decrease in bone resorption 
and an increase in bone mass. Therefore, it is suggested that the low miR-503 expression in 
postmenopausal osteoporosis patients will promote RANKL-induced osteoclastogenesis, and 
consequently, bone resorption rate will increase leading to net bone loss [42].
MiR-221 expression is downregulated in postmenopausal osteoporotic bone samples com-
pared to nonosteoporotic bones. In BMP-2-induced osteoblastogenesis, the overexpression 
of miR-221 resulted in reduced expression of key osteoblast markers, including osteocalcin 
(OC), alkaline phosphatase (ALP), and collagen type Iα 1 (COL1A1), whereas knockdown 
of miR-221 promoted the activity of OC, ALP, and COL1A1 [43]. The later study identified 
Runx2 as a potential target of miR-221. Therefore, this provided an evidence that miR-221 
serves as the negative regulator of osteoblast differentiation and contributes to the osteoporo-
sis pathogenesis through the regulation of Runx2 action [44].
Tumor necrosis factor α (TNF-α) inhibits MSC osteogenic differentiation and bone formation 
in estrogen deficiency-induced osteoporosis with a poorly understood mechanism. A study 
conducted by Yang et al. showed that the expression of miR-21 is dramatically downregulated 
in mesenchymal stem cells (MSCs), and this downregulation is due to the suppression by 
TNF-α during the osteogenesis of MSCs. Moreover, miR-21 has been proved to stimulate the 
osteoblast differentiation of MSCs by targeting protein sprouty homolog 1 (Spry1), a negative 
regulator of osteoblast differentiation from MSCs. The later study also demonstrated that the 
overexpression of miR-21 is able to partially rescue the osteogenic impairment induced by 
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TNF-α in MSCs. Furthermore, in vivo treatment with anti-TNF-α in OVX mice has increased 
bone formation by upregulating miR-21 expression, suppressing Spry1 expression and reme-
diating the inflammatory conditions. Thus, this study indicated that TNF-α impairs osteo-
blastic bone formation by suppressing miR-21 expression in estrogen deficiency-induced 
osteoporosis [45].
A study conducted by Wang et al. showed that glucocorticoid-treated mice experienced low 
bone mass density (BMD) and bone mass content (BMC). Glucocorticoid treatment also signif-
icantly resulted in the decrease of bone matrix COL1A1 expression, an increase in dickkopf-1 
(Dkk-1) expression and a reduction in miR-29a expression [46]. MiR-29a plays important role 
in osteoblast differentiation and bone homeostasis by regulating the expression of Wnt inhibi-
tor Dkk-1 [23]. In vivo miR-29a precursor treatment was able to reduce the glucocorticoid-
stimulated BMD and BMC, attenuate glucocorticoid-induced loss of trabecular bone volume 
fraction, decrease the porosity of cortical bone, and rescue the adverse effect of glucocorti-
coid on peak load of bone tissue. The treatment with miR-29a inhibitor, however, provided 
opposite effects [46]. Thus, miR-29a is important in protection against glucocorticoid-induced 
osteopenia, which may lead to osteoporosis by regulating the activity of Wnt signaling and 
Dkk-1 in osteoblast differentiation and bone mineralization [23, 47].
3.3. Bone collagen matrix retardation: osteogenesis imperfecta
Osteogenesis imperfecta (OI) is a heterogeneous group of inherited connective tissue disorder 
that occurs in about 1 in 10,000 to 20,000 live births [47]. OI is characterized with clinical 
features such as susceptibility to bone fractures due to low bone mass, reduced bone strength, 
or quality and bone deformity [48]. In addition, blue sclerae, short stature, dentinogenesis 
imperfecta (DI), and hearing loss are other clinical manifestations of OI [49]. The pathogenesis 
of OI involves the most prevalent autosomal dominant mutation of COL1A1 and COL1A2 
genes encoding the alpha1 and alpha2 chains of type I procollagen [50]. Type I procollagen 
is the major bone structural protein, and therefore, the mutation of COL1A1 and COL1A2 
genes may have direct link with serious defects or abnormalities including deformities of col-
lagen primary structure, insufficient bone collagen quantity, deviated posttranslational modi-
fication, folding, intracellular transport or matrix incorporation, and bone mineralization. 
Recessive OI is caused by defects in genes that encode for protein products, which interact 
with type I collagen [51]. There are four well characterized types (I, II, III, and IV) of COL1A1/
COL1A2-linked OI based on different clinical and genetic presentations [52].
Wang et al. performed the preliminary screening of more than 100 bone-related miRNAs in 
serum of 22 OI patients. The results showed that three miRNAs (miR-26a, miR-30e, and miR-
21) were upregulated and eight miRNAs (miR-34c, miR-29a, miR-29b, miR-489, miR-133a, 
miR-145, miR-210, and miR-1297) were downregulated in OI patients compared to healthy 
controls. MiR-29a has a universal lower level in the patient group, whereas miR-26a had a 
universal upper level. This discovery of altered expression of bone-related miRNAs in OI 
patients’ serum profile may become promising miRNA biomarkers for the diagnosis of 
OI. Although this study did not verify on the relationships of these differentially expressed 
miRNAs and their potential target genes, the previous studies have showed that these miR-
NAs may target a range of gene involved in osteogenic signaling pathways such as BMP, Wnt, 
RANKL, and TGFβ/activin [53].
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MiR-29b has been shown to modulate osteoblast differentiation by downregulating the activ-
ity of COL1A1, COL5A3, and COL4A2 and attenuate the collagen protein accumulation 
during the mineralization phase of bone formation [24]. Kaneto et al. performed a sequence 
analysis on the coding region and intron/exon junctions of COL1A1 and COL1A2 genes in 
five independent patients with type I and type III OI. The sequence analysis has identified 
eight novel mutations, which may contribute to OI phenotype. Interestingly, Kaneto et al. also 
determined that the expression levels of COL1A1 and miR-29b are reduced in both type I and 
type III OI patients. Therefore, it is speculated that miR-29b expression is not an essential for 
sustaining osteoblastogenesis [54].
3.4. Enlarged, weak bone deformation: Paget’s disease of bone
Paget’s disease of bone (PDB) is a localized disorder of highly exaggerated bone turnover 
characterized by excessive bone resorption action by osteoclasts within pagetic lesions, fol-
lowed by an increase in disorganized new bone formation by osteoblasts [55]. This action will 
eventually result in marrow fibrosis, highly vascular, weak, enlarged, and disorganized bone 
deformation [55, 56]. The highly fibrous woven bone with reduced mechanical strength and 
disorganized structural integrity tends to increase the risk of bone deformity and fracture [56]. 
Frequently, PDB patients are elderly aged more than 50 years and tend to slightly predomi-
nate in males [57]. Mutations in genes encoding for the components that modulate the RANK/
NF-κB signaling pathway are most likely to contribute to the development of PDB. These 
genes are sequestosome 1 gene (SQSTM1), tumor necrosis factor receptor superfamily mem-
ber IIA (TNFRSF11A), valosine-containing protein (VCP), and tumor necrosis factor receptor 
superfamily member IIB (TNFRSF11B) [55].
However, the regulatory roles of miRNAs in PDB remain unknown. Bianciardi et al. performed 
a serum miRNA expression profile in peripheral blood mononuclear cells (PBMCs) from 20 
PDB patients. The results showed that 22 miRNAs were significantly upregulated with a fold 
change above three (miR-31, miR-32, miR-124a, miR-132, miR-182, miR-221, miR-339, miR-
345, miR-410, miR-451, miR-485.3p) or between 2 and 3 (miR-19a, miR-30b, miR-30c, miR-27a, 
miR-125a, miR-146a, miR-148a, miR-200c, miR-223, miR-301, miR-365) when compared to non-
pagetic controls. Among the 22 miRNAs, these 14 miRNAs (miR-19a, miR-miR-27a, miR-30c, 
miR-32, miR-125a, miR-132, miR-200c, miR-221, miR-223, miR-301, miR-345, miR-365, miR-410, 
and miR-485-3p) showed significantly higher expression in patients that experienced Q16STM1 
mutation [58].
4. Current status and perspectives of microRNA in bone cancer 
diagnosis and therapy
In 2010, the first microRNA-targeting drug—miravirsen (SPC3649), a locked nucleic acid 
(LNAs) ribonucleotides antagomir that targets miR-122 had entered clinical trial and is cur-
rently in phase II clinical trial to treat chronic hepatitis C (HCV+) patients (ClinicalTrials.gov 
Identifier: NCT02508090) [59]. The occurrence of the first miRNA-based clinical trial had led 
to the insight that miRNAs can serve as promising therapeutic tools and perhaps as the next 
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magic bullet. The side effects arise from current conventional treatments of bone cancer that 
also lead to the path of translating the bone cancer miRNA-based therapeutic approaches 
from the benchworks to the clinical settings.
MRX34, a miRNA mimic encapsulated by liposomal nanoparticle developed by Mirna 
Therapeutics, appeared as the first miRNA mimic that had reached phase 1 clinical study 
in year 2013 for the treatment of primary liver cancer and other malignancies including 
multiple myeloma through functional restoration of endogenous miR-34a as an oncosup-
pressor (ClinicalTrials.gov Identifier: NCT01829971) [60]. MiR-34a is often suppressed or 
showed to reduce expression in various cancer types, coupled with the loss of p53 function 
that transcriptionally control its expression [61]. There are a wide varieties of oncogenes such 
as cyclin-dependent kinase (CDK) 4/6, Wnt 1/3, B-cell lymphoma 2 (BCL2), MYC, cyclin D1 
(CCND1), CD44, and histone deacetylase 1 (HDAC1) that are responsible for unregulated cell 
cycle progression and proliferation, anti-apoptosis, metastasis, chemoresistance, cancer cell 
self-renewal, and oncogenic transcription, which can be downregulated by miR-34a [62, 63]. 
In a phase I clinical trial, adult patients with advanced solid tumors refractory to standard 
conventional treatment were given a standard 3 + 3 dose escalation trial by which MRX34 was 
infused to the patients twice a week (BIW) for a period of 3 weeks in a four-week-cycle. The 
phase 1 results showed that MRX34 has a tolerable toxicity or safety profile and supportive 
evidence of anti-tumor activity in a subset of patients with refractory advanced solid tumors. 
The patients generally experienced mild adverse effects such as fever, fatigue, back pain, nau-
sea, anorexia, diarrhea, and vomiting after the treatment [64].
To date, there has been no available miRNA-based diagnostic tests or treatments for bone can-
cers’ management. However, miR-34 anti-tumor activity had been demonstrated in numer-
ous cancer types including bone cancer and multiple myeloma, and therefore, providing a 
fascinating insight into the introduction of miR-34a mimic for the treatment of bone cancers.
The expression of tumor suppressive mir-34 and miR-122 are downregulated in osteosarcoma 
cells contrasting to healthy normal cells. Xiao et al. has introduced miRNA response elements 
(MREs) of miR 34 and miR 122 in osteosarcoma cells through the employment of adenovirus 
to enable the selective expression of tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL). This study reported that the adenovirus (Ad) TRAIL-34-122 resulted in higher 
apoptotic and cytotoxicity levels in the osteosarcoma cells, compared to the normal cells by 
selectively expressing TRAIL in miR-34 and miR-122 modulated fashion. The following in 
vivo study in BALB/c nude mice further indicated that Ad-TRAIL-34-122 is able to reduce 
osteosarcoma xenografts’ growth without causing significant liver toxicity [65]. Additionally, 
Gaur et al. reported that chitosan nanoparticle-mediated delivery of miR-34a mimic preserves 
bone integrity and reduces tumor growth in a tumor established, intrafemoral nude mice 
model that represented prostate cancer bone metastasis [66].
Furthermore, Martino et al. has evaluated the activity of synthetic miR-34a in multiple 
myeloma cells. This study demonstrated that transfection with miR-34a mimic tends to inacti-
vate the early expression of prosurvival and proliferative kinases Erk-2 and Akt. The reduced 
expression of Erk-2 and Akt is followed by the downregulation of caspase-6/3 expression, 
which can next induce apoptosis in multiple myeloma cells. Martino et al. subsequently tested 
the efficiency of miR-34a mimic delivery by encapsulating the mimic in stable nucleic acid 
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lipid particles (SNALPs). SNALP-encapsulated miR-34a mimic is highly efficient with its anti-
tumor activity in both multiple myeloma cells and in in vivo SCID mice bearing human mul-
tiple myeloma xenografts by showing reduced expression of miR-34a target notch 1 homolog 
(NOTCH1) and the absence of cytotoxicity effect [67].
5. Future prospects of microRNAs in the treatment of bone disorders 
and its potential
Although the publication of research findings on microRNAs in bone disorders are still lim-
ited, the fast-growing list of literatures indicates the significance of miRNAs in the regulation 
of bone biology and bone disorders. This has led to the advancement of research to explore 
potential relevance of miRNAs as diagnostic biomarkers and therapeutics. In this section, 
the potential of miRNAs as the biomarkers and therapeutic agents will be focused on cancer-
related bone disorder (osteosarcoma) and noncancer-related bone disorder (osteoporosis).
5.1. MicroRNAs as diagnostic biomarkers
The comprehensive expression profile of key microRNAs in different bone disorders has the 
potential to increase the accuracy of the prognosis and diagnosis of bone disorders in combi-
nation with other conventional diagnostic approaches.
Hu et al. reported that a total of 268 miRNAs were dramatically dysregulated between human 
osteosarcoma cell line, MG-63, and human osteoblast HOB cell line. Five miRNAs (miR-9, 
miR-99, miR-195, miR-148a, and miR-181a) were validated to be overexpressed and four of 
these miRNAs (miR-143, miR-145, miR-335, and miR-539) were validated to be downregulated 
in the human OS MG-63 cell lines compared to osteoblast HOB cell lines. The bioinformatics 
analysis showed that the target genes of these nine miRNAs are associated with multiple 
cancer-related events including cell proliferation, differentiation, cell cycle, apoptosis, signal-
ing, migration, and invasion [68].
Another study by Jones et al. using pretreatment biopsy samples from conventional (osteo-
blastic/fibroblastic) osteosarcoma patients and control samples of healthy bone tissue showed 
that 34 miRNAs were significantly dysregulated with 11 having higher expression and 23 
having lower expression among the osteosarcoma group. MiR-181a and miR-181b were 
the most upregulated miRNAs in osteosarcoma group while miR-29b, miR-451, and miR-
16 were among the most downregulated. The miRNA signature profile in the sample of 
metastatic osteosarcoma group compared to nonmetastatic osteosarcoma group showed that 
higher expression of miR-27a and miR-181c* was found in patients with metastatic tumor. 
Additionally, higher expression of miR-451 and miR-15b was associated with chemosensitive 
patients compared to chemoresistant samples. In vitro and in vivo functional validation in 
osteosarcoma cell lines confirmed the tumor suppressive role of miR-16 and the pro-met-
astatic role of miR-27a. The analysis of target genes of these miRNAs indicated that these 
miRNAs may target several known osteosarcoma-related genes that regulate transcription, 
cell cycle control, and cancer signaling pathways [69].
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Li et al. identified potential miRNA biomarkers for the early diagnosis and relapse prediction 
of osteosarcoma by developing a serum-based miRNA profile. All the putative miRNAs were 
verified through RT-qPCR, and the expression of seven miRNAs (miR-106a-5p, miR-16-5p, 
miR-20a-5p, miR-425-5p, miR-451a, miR-25-3p, and miR-139-5p) was found to be downregu-
lated in the serum of OS patients compared to the healthy control. These miRNAs are also cor-
related with other type of cancer pathogeneses such as lung carcinoma, colorectal carcinoma, 
breast carcinoma, nasopharyngeal carcinoma, etc. [70].
Yuan et al. demonstrated that miR-21 expression was significantly higher in serum from 
osteosarcoma patients compared to healthy controls as measured by RT-qPCR. The high 
expression of miR-21 is associated with aggressive Enneking tumor staging, neoadjuvant che-
motherapeutic resistance, and reduced overall survival rate [71]. Previous studies indicated 
that miR-21 has influences on the cell proliferation, cell cycle progression, tumor metastatic 
behavior, and susceptibility to chemotherapeutic treatment [43, 72–74]. These tumor-promot-
ing behaviors of miR-21 was due to its targeting regulatory roles on a vast number of tumor 
suppressive genes such as phosphatase and tensin homolog protein (PTEN) [72], myris-
toylated alanine-rich protein kinase C substrate protein (MARCKS) [43], programmed cell 
death 4 protein (PDCD4) [73], and cell division cycle 25 homolog A protein (CDC25A) [74].
Dong et al. showed that expression of miR-223 was significantly reduced in the serum of 
osteosarcoma patients and osteosarcoma cell lines compared to healthy controls as measured 
by RT-qPCR. Osteosarcoma patients with lower expression of serum miR-223 tend to have 
distant metastasis, more advanced clinical stages, and shorter survival time [75]. Furthermore, 
it has been demonstrated that miR-223 may play an important role in the regulation of epi-
thelial cell transforming sequence 2 (Ect2) signaling, an important pathway for osteosarcoma 
pathogenesis in terms of cell cycle progression, proliferation, recurrence, and poor chemo-
therapeutic responses [76].
Lian et al. performed TaqMan low-density array (TLDA) and RT-qPCR on plasma samples 
derived from osteosarcoma patients before surgery, patients after 1 month of surgery and 
healthy individuals. The results showed that four plasma miRNAs (miR-195-5p, miR-199a-3p, 
miR-320a, and miR-374a-5p) were significantly upregulated in the presurgical osteosarcoma 
patients. The expression level of these four plasma miRNAs were decreased after surgical 
removal of the tumors, suggesting the potential of these miRNAs as the biomarkers for osteo-
sarcoma. Additionally, circulating miR-195-5p and miR-199a-3p were correlated with metas-
tasis status whereas miR-199a-3p and miR-320a were correlated with histological subtype [77]. 
Besides, it has been discovered that miR-195-5p involved in the inhibition of osteosarcoma 
cell migration and invasion by targeting fatty acid synthase (FASN) [78], while miR-199a-3p 
regulated the p53 signaling pathway and inhibits osteosarcoma cell growth, migration, and 
induce apoptosis [79, 80].
5.2. MicroRNAs as therapeutic agents or targets
Growing lists of in vitro and in vivo studies on the regulatory roles of microRNAs in bone dis-
orders, which conducted by various research teams, have supported miRNAs as the potential 
therapeutics candidates. However, specific, efficient, and safe delivery of miRNA to its target 
MicroRNAs in Bone Diseases: Progress and Prospects
http://dx.doi.org/10.5772/intechopen.79275
89
sites is crucial for the translation of miRNA-based therapeutics strategies. Effective delivery 
systems in various bone disorder models had been observed by the application of biomaterial 
constructs, viral vectors, nanoparticles, and polymers with the potential to restore the normal 
functions of bone homeostasis and carcinogenesis.
The expression of miR-199a-3p, which may inhibit tumor cell growth, is reduced in osteosar-
coma cells. Zhang et al. developed a lipid-modified dextran-based polymeric nanoparticle 
platform for encapsulation of miR-199a-3p and another potent tumor suppressive miRNA, 
let-7a, and transfected into osteosarcoma cells lines, KHOS and U-2OS. Western blot analysis 
and 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) assay showed that 
dextran nanoparticles loaded with miRNAs could efficiently downregulate the expression of 
mechanistic target of rapamycin (mTOR) and Met proteins and effectively inhibit the growth 
and proliferation of osteosarcoma cells [81].
MiR-143 expression is downregulated in 143B human osteosarcoma cell line, an osteosarcoma 
cell line with high metastatic tendency to the lung. Osaki et al. inoculated the 143B osteosar-
coma cells transfected with firefly luciferase gene (143B-luc) into athymic mice in order to 
develop a primary tumor and spontaneous lung metastasis. Then, systemic administration of 
miR-143 mimic and miR-negative control 1 (NC1) mixed with atelocollagen was performed on 
the osteosarcoma mice model to study the therapeutic potential of miR-143 against spontane-
ous lung metastasis of osteosarcoma. After 1 week, the luciferase signal was detected only at 
the right knee primary lesion where 143B-luc cells were inoculated. After 2 weeks, one out of 
four mice administered with miR-NC1 was detected with luciferase signal at the pulmonary 
area indicating lung metastasis, whereas no luciferase signal was observed in mice injected 
with miR-143 mimic. After days 19–20, two out of 10 mice injected with the miR-NC1 control 
died due to lung metastasis. At third week, six of the eight live mice administered with miR-
NC1 control were identified with lung metastasis, while contrastingly, only two out of 10 mice 
injected with miR-143 mimic displayed lung metastasis. Furthermore, the tumor weight and 
the expression of proliferative cell nuclear antigen in primary tumor showed no significant 
difference between both groups (miR-143 mimic and miR-NC1 control). Therefore, all these 
data showed that miR-143 mimic suppresses lung metastasis from a primary tumor but did 
not have effect on the primary tumor cell proliferation. Additionally, it is speculated that the 
downregulation of miR-143 may promote lung metastasis of human osteosarcoma cells by pro-
moting MMP-13 upregulation [82]. Shimbo et al. introduced synthetic miR-143 into MSC cells 
and increased the amount of exosome-formed miR-143 in the conditioned medium. The trans-
fection of 143B osteosarcoma cell lines with extracellular miR-143 in the conditioned medium 
from MSCs (exosome-formed miR-143) reduced the migration ability of osteosarcoma cells 
compared to the control. In addition, Shimbo et al. also showed that the transfection efficiency 
of exosome-formed miR-143 was less than that attained with the lipofection. Nevertheless, 
migration assay performed on the 143B osteosarcoma cells showed that the inhibitory effect on 
cell migration was similar between exosome and lipofection method [83].
Jiang et al. constructed lentiviral vectors overexpressing and silencing miR-126. Both of the miR 
126 overexpressing and silencing lentiviral vectors were then transfected into MG63 and U-2 OS 
osteosarcoma cell lines. This study aimed to determine the interlink between cisplatin (DDP) 
and methotrexate (MTX) osteosarcoma chemotherapeutic drugs and miR-126 on the effect to 
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inhibit osteosarcoma cell proliferation and apoptosis. The results showed that DDP and MTX 
induce apoptosis and inhibit the cell cycle of osteosarcoma cell lines at a greater efficiency in 
miR-126 overexpressing manner. Nonetheless, DDP and MTX did not significantly impact the 
apoptosis and cell proliferation in the miR-126 silenced group. On that account, it is suggested 
that miR-126 may strengthen the sensitivity of osteosarcoma cell to DDP and MTX. However, 
the regulatory mechanisms behind this process still remain to be discovered [84].
Cai et al. developed polyurethane (PU) nanomicelles drug carrier modified with Asp8 acidic 
peptide (Asp8-PU-anti-miR214) for targeted delivery of anti-miR-214. Polyurethane (PU) is a 
linear polymer composed of organic units molecularly linked by carbamate (urethane) group 
[85]. Besides, it is known that PU tends to have high compatibility in living system by not being 
toxic or reactive and have high mechanical flexibility [85–88]. The highly negatively charged 
peptide Asp8 has also been accounted as an excellent targeting tool of bone resorption area 
[89]. In this study, miR-214 was chosen due to its regulatory role in bone remodeling by which 
the elevated expression in vivo was associated with reduced bone formation in aged patients. 
This is due to the direct targeting action of miR-214 on activating transcription factor 4 (ATF4), 
which enable the inhibition of osteoblast activity [90]. Apart from that, miR-214 also modulates 
osteoclast differentiation by targeting the PTEN-PI3k-Akt pathway [91]. Asp8-PU-anti-miR214 
delivery system to osteoclasts at the bone resorption surface of ovariectomized (OVX) osteo-
porosis mice model was able to improve the bone microarchitecture, increased bone mass, and 
decreased osteoclast number. Above and beyond, a number of osteoclast-related genes includ-
ing tryptophan RNA-binding attenuation protein (TRAP) and cathepsin K (CTSK) were success-
fully downregulated by the anti-miR-214. Interestingly, Asp8-PU-anti-miR214 was also proven 
as a potential drug delivery candidate that does not overt toxicity or elicit an immune response. 
Therefore, Asp8-PU serves as a potential bone-resorption surface-targeting delivery system for 
the treatment of postmenopausal osteoporosis and osteoclast-stimulated bone disorders [85].
Zhang et al. designed a hyperbranched polymer (HP) and miR-26a (HP/miRNA) nanosized 
polyplexes, which were encapsulated in biodegradable microspheres to overcome problems 
with uncontrolled release and achieved the controllable two-stage delivery strategy (micro-
spheres and polyplexes). Microspheres attach to cell-free nanofibrous polymer 3D scaffolds 
to prevent off-target effects of the miRNA delivery. The 3D scaffolds were implanted into 
osteoporotic mice model, and the results showed that this technology was able to regenerate 
critical-sized bone with low cytotoxicity effect by targeting glycogen synthase kinase 3 beta 
(Gsk-3β) to activate the osteoblastic activity of endogenous stem cells [92].
Overexpression of miR-140* and miR-214 was detected in bone marrow-derived MSCs 
isolated from ovariectomized rats (OVX-BMSCs). Li et al. demonstrated that engineered 
OVX-BMSCs expressing the hybrid baculovirus-mediated miRNA sponges can continu-
ously antagonize cellular miR-140* and miR-214 levels in vitro. At the same time, the attenu-
ation of miR-140* and miR-214 expression can also efficiently support the osteogenesis of 
OVX-BMSCs and intensify the capability of OVX-BMSCs to suppress osteoclast maturation. 
Remarkably, the osteoinductive effect of suppressing miR-214 was more potent compared 
to miR-140* suppression. This study also discovered that the allotransplantation of miR-214 
sponges-expressing OVX-BMSCs in osteoporotic rat models with a femoral metaphysis found 
with critical-size bone defect was able to improve the likelihood of bone healing, remodeling, 
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and bone quality at 4 weeks postimplantation. Moreover, co-expression of bone morphogenic 
protein 2 (BMP2) and miR-214 sponges in OVX-BMSCs can synergistically enhance the bone 
formation and healing in osteoporotic rats [93].
6. Challenges
Although recent studies reveal that microRNA has the potential to become diagnostic 
biomarker and effective therapeutic agents for bone diseases, there are still challenges for 
developing miRNA-based treatment. Since each miRNA may regulate many different mRNA 
targets and the expression of target genes might be controlled by different miRNAs, it became 
an obstacle to identify all targets and miRNAs involved in bone diseases [94]. Moreover, miR-
NAs are cancer type specific, they may perform as oncogene or tumor suppressor in different 
cell types, and thus result in off-target effects of miRNAs [95]. Garzon et al. reveals that miR-
29 mimics serve as anticancer agents and regulate in bone growth; meanwhile, they target 
several tumorigenesis pathways like proliferation (CDK6), methylation (DNMT1, DNMT3a 
and b), and apoptosis (MCL-1) [96].
Currently, one of the major challenges facing by the researches is the mechanism of in 
vivo delivery. There are lots of mechanical and biological barriers to cope with for success 
transferring of miRNA into the target genes. The first barrier is the abnormal tumor vessels 
in leaky structure, which cause the poor blood perfusion and affect the delivery of naked 
miRNA. In addition, the extracellular matrix is very complex, consisting of tumor-associated 
macrophages and monocytes, which can trap miRNA in capsule and have the ability to 
hinder the miRNA to target the cancer cells. MiRNA is also susceptible to nucleases such 
as serum RNase A-type nucleases, which break phosphodiester bonds between nucleotides 
[97]. Furthermore, the small-sized miRNA is easily filtered by kidney and cleared in the 
blood circulation [98]. Hence, the instability of miRNAs needs to be overcome in order for 
the miRNAs to reach the target genes. Even if miRNAs are successfully transferred into the 
target tissue, the uptake of miRNAs into the cells is not guaranteed. The miRNA oligonucle-
otides consist of negative charges, and it prevents them from passing through the plasma 
membranes of the target cells [96]. Strategy to improve endosomal escape should also be 
taken in consideration since the endocytosis mechanism that capsulated miRNA causing 
degradation might be happened [97].
Besides delivery considerations, the autoimmunological pathways are necessary to be empha-
sized. MiRNAs are recognized as foreign particles by immune system in the body, which 
will trigger the adaptive or innate immune responses causing unpredictable toxicities [99]. 
Chen et al. reported that miRNA duplexes can trigger toll-like receptors (TLRs) to secrete the 
inflammatory cytokines and type I interferons. Activation of TLRs 3, 7, and 8 by single- or 
double-stranded RNAs promotes innate and adaptive immune systems and also prepare the 
surrounding immune cells, for instance, natural killer cells, dendritic cells, monocytes, B cells, 
etc., to increase the sensitivity to RNA stimulation [97]. The immune responses toward the 
miRNA still required further studies.
Numerous findings of miRNA are based on in vitro studies using cell lines and are not fully 
validated in in vivo. In addition, the major methods used to measure miRNA levels are 
Transcriptional and Post-transcriptional Regulation92
quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) and micro-
array analysis, and there is no standardized techniques to measure the miRNA expression 
levels [38]. Further techniques need to be optimized for better miRNA detection and analysis.
Despite there are many challenges, the potentials of miRNA as a diagnostic tool and treat-
ment for bone diseases look promising. We believe that in the next few years, researches will 
be able to develop efficient delivery methods of the miRNA to its specific target site with 
minimum or no side effect.
7. Conclusions
As a conclusion, microRNA plays important roles in bone development and maintenance. 
MiRNA dysregulation leads to the pathogenesis of various bone diseases. Nowadays, miRNAs 
are being excavated as new directions for diagnostic biomarkers and drug targets to cure bone 
diseases. However, there are still many limitations and barriers for the development of miRNA-
based biomarkers and therapeutics. Further investigations are needed to understand the miRNA 
gene regulation in bone and to overcome the challenges faced in miRNA delivery systems. 
MiRNA studies not only provide new eras of basic bone biology researches, but also contribute 
to new diagnostic and therapeutic methods into clinical practice to various bone diseases.
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